# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Joanne Wuensch maintains Haemonetics (NYSE:HAE) with a Buy and lowers the price target from $78 to $64.
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $86 price target.
Raymond James analyst Andrew Cooper downgrades Haemonetics (NYSE:HAE) from Strong Buy to Outperform and lowers the price tar...
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target f...